Schema-driven pharmacokinetic models, automated safety checks, and cryptographic audit trails — purpose-built for the daily clinical, compounding, and lab workflows that peptide pharmacies actually run. Third-party validation in progress.
A $53 billion peptide therapeutics market collides with the most aggressive FDA enforcement cycle in compounding history. The clinics, pharmacies, and labs that survive will be the ones whose compounding operations and clinical documentation are computationally auditable from formulation to patient.
Global market approaching $70B by 2031. Metabolic, oncology, and personalized peptide therapies are driving unprecedented demand through compounding channels.
FDA has resolved national GLP-1 shortages and ended enforcement discretion. Compounders operating on shortage exemptions face immediate compliance requirements.
Telehealth platforms, 503B facilities, and even contract labs cited for potency failures, sterility gaps, and misleading marketing of compounded peptides.
Enterprise PBPK platforms serve big pharma at enterprise cost. Compounders and clinics rely on spreadsheets, manual calculations, and undocumented shortcuts.
Between the pharmacokinetic science a compounder should document and the tools they actually have access to for daily clinical and lab operations, there is a dangerous void.
Enterprise pharmacokinetic platforms — Simcyp, GastroPlus, NONMEM — were built for billion-dollar drug development programs. They carry six-figure price tags, require specialist operators, and produce outputs formatted for NDA submissions, not pharmacy SOPs. They were never designed for the compounding pharmacist checking a dosing rationale, the lab tech verifying unit consistency, or the QA lead assembling inspection evidence.
On the other end, peptide clinics and 503A/503B compounders face daily operational questions — What is the accumulation ratio at steady state? Are we within the therapeutic window for a renally-impaired patient? Does this formulation maintain dimensional consistency across the compounding record? — but answer them with Excel, institutional memory, and hope.
FDA's post-shortage enforcement posture makes this untenable. Warning letters increasingly cite unsupported dosing rationale, subpotent releases, and inadequate out-of-specification handling. The question is no longer whether you have the right answer — it's whether you can prove it.
"The issue is not that compounders lack pharmacological knowledge. The issue is that their knowledge leaves no trace."
A computational engine built for clinical compounding, lab operations, and AI agents alike — 717 deterministic tools across 29 namespaces for dosing verification, safety profiling, formulation QA, and generating inspector-ready evidence. Every result hashed, every chain certifiable. Third-party validation in progress.
Define model templates with typed parameters, bind patient-specific values, and let six automated pre-flight checks — completeness, domain, semantic, dimensional, assumption, and solvability — validate before any computation runs.
Five post-flight safety checks evaluate every instantiated model: constraint bounds with margins, steady-state accumulation ratios, compound-risk perturbation for DDIs, local sensitivity coefficients, and kinetic regime discrimination.
Pint-backed unit propagation through every expression. Buckingham Pi theorem for scale-invariant summaries. Automatic dimensional verification flags mg/mL vs. mg/L mismatches before they reach a patient.
Every computation is a node in a Merkle DAG. At session end, an HMAC-SHA256 signed certificate captures the full provenance chain — who computed what, with which inputs, producing which outputs. Offline-verifiable. Inspector-ready.
53 visualization tools including pharma-specific outputs: VPC plots, goodness-of-fit panels, forest plots with confidence intervals, spaghetti fits, Kaplan-Meier curves, dose-response, and sensitivity tornados.
33 cheminformatics tools for peptide-specific lab workflows: molecular descriptors and fingerprint similarity for identity verification, QSAR modeling for property prediction, and ADMET-style profiling for formulation assessment. Same engine extends into novel compound research and clinical trial support as your operation scales — a capability we are actively building toward.
Consider a 503B outsourcing facility validating a BPC-157 subcutaneous peptide formulation for a clinic network. The pharmacist needs to demonstrate therapeutic window compliance, accumulation safety, and dimensional consistency — with evidence that survives an FDA inspection.
Five steps. Full audit trail. Zero spreadsheets.
Functo's schema classifier identifies the elimination pathway and recommends the appropriate 1-compartment SC model template.
AUTO-ROUTEDBind patient parameters (weight, eGFR, dose). Six pre-flight checks run automatically: completeness, domain, semantic, dimensional, assumptions, solvability.
6/6 PASSEDPost-flight bounds check evaluates Cmax, Css, and trough concentrations against the therapeutic window. Margin of safety computed per constraint.
WITHIN BOUNDSAccumulation ratio R calculated at the dosing interval. Sensitivity tornado identifies which parameters most affect steady-state exposure.
R = 1.34HMAC-SHA256 certificate generated over the computation DAG. Publication-quality report exported with provenance chain intact.
CERTIFIEDFuncto capabilities mapped directly to regulatory requirements facing peptide compounders and clinics.
| Regulatory Requirement | Framework | Functo Capability | Covered |
|---|---|---|---|
| Dosing rationale documentation | 503A / 503B | Schema-driven PK models with pre-flight checks | ✔ |
| Dimensional consistency | USP <797> | Pint unit propagation + Buckingham Π analysis | ✔ |
| Steady-state safety | 503B cGMP | Accumulation ratio + bounds check with safety margins | ✔ |
| Drug interaction analysis | 503A / 503B | Compound-risk perturbation with symbolic re-evaluation | ✔ |
| Parameter sensitivity | cGMP / QA | Local sensitivity coefficients + tornado visualization | ✔ |
| Computation audit trail | 21 CFR Part 11 | HMAC-SHA256 signed Merkle DAG certificates | ✔ |
| Reproducible evidence | FDA Inspection | Session checkpoints, run comparison, provenance export | ✔ |
| Formulation optimization | USP <797> | Peptide descriptors, QSAR, stability-indicating analytics | ✔ |
| Peptide identity & characterization | Lab / QC | Molecular descriptors, fingerprint similarity, QSAR property checks | ✔ |
| Publication-ready reporting | QA / Legal | 53 pharma visualization tools + HTML/PDF export | ✔ |
Four converging forces make computational infrastructure not a luxury, but a survival requirement for peptide compounders.
FDA resolved semaglutide and tirzepatide shortages. Enforcement discretion for compounding "essentially a copy" has expired. Compounders must now justify every formulation on its own scientific merits.
Simultaneous enforcement from FDA inspections, state boards, payer audits, and innovator litigation (Novo Nordisk, Eli Lilly) narrows the viable operating corridor for undocumented operations.
The compounding market is splitting: high-compliance, QA-invested operations win institutional contracts, while undocumented "peptide mills" face existential legal and regulatory risk.
Functo is built as an MCP server — AI-callable, deterministic, and auditable from day one. The same platform powering your compounding operations today extends into novel compound research and clinical trial support as we build that capability next.
"In a post-shortage regulatory environment, the peptide compounder's most valuable asset is not their cleanroom — it's the provenance chain connecting their compounding operations to their patient."
— nnLabs, 2026Functo does not replace the pharmacist's judgment. It captures it — in a form that is reproducible, verifiable, and defensible. Every model schema, every safety check, every sensitivity analysis becomes part of an immutable computation record that answers the only question an inspector will ever ask:
"Show me how you know this is safe."
And as your operation grows, the same infrastructure extends. We are actively building toward novel compound research and clinical trial support — so the platform that runs your pharmacy today becomes the platform that powers your pipeline tomorrow.
Schedule a demonstration of the Functo platform. See your formulations modeled, your dosing verified, and your evidence certified — all in one session.